Phinomics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Phinomics is pioneering a novel approach to precision oncology by targeting the 'hidden 50%' of cancer biology, specifically extrachromosomal circular DNA (ecDNA). The company's proprietary platform isolates and decodes ecDNA and cryptic proteins, integrating this data with other molecular layers via explainable AI to build a comprehensive model of cancer's decision-making architecture. This approach aims to dramatically improve target discovery and biomarker prediction, addressing the high failure rate in oncology drug development. Phinomics is a private, pre-clinical stage company building its therapeutic pipeline and platform capabilities from its San Diego headquarters.

Oncology

Technology Platform

Proprietary 'Cancer Intelligence Platform' that isolates and decodes extrachromosomal circular DNA (ecDNA) and cryptic micro-proteins. It integrates this unique data layer with multi-modal molecular datasets (genomics, transcriptomics, proteomics) and uses explainable AI to model causal biological networks for target and biomarker discovery.

Opportunities

The company operates in the large and growing precision oncology market, addressing the root cause of high drug failure rates.

Its unique focus on ecDNA taps into a major, historically untapped driver of cancer aggressiveness and resistance.

The platform has the potential to generate both novel therapeutics and high-value predictive biomarkers, creating multiple paths to value creation.

Risk Factors

The platform's novel approach is unproven in generating successful clinical drugs, representing high technical and translational risk.

As a private, pre-revenue company, it faces significant funding and execution risks in building a therapeutic pipeline.

Competition in AI-driven drug discovery and ecDNA analysis is intensifying.

Competitive Landscape

Phinomics competes with other AI/ML-driven biotechs (e.g., Recursion, Exscientia) and genomics platform companies. Its specific focus on ecDNA places it against academic leaders and a small number of startups (e.g., Boundless Bio) targeting this biology. Differentiation hinges on its claimed 100X resolution in ecDNA detection and its integrated, multi-modal AI approach.

More companies in RNA Therapeutics (non-mRNA) →More companies in United States →